Akari Therapeutics Plc
(NASDAQ : AKTX)

( )
AKTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.06%35.230.9%$1166.00m
JNJJohnson & Johnson 1.89%147.960.7%$1011.63m
BMYBristol-Myers Squibb Co. 0.24%57.891.0%$902.16m
MRKMerck & Co., Inc. 1.14%78.230.7%$750.67m
ABBVAbbVie, Inc. 2.31%98.911.9%$715.84m
LLYEli Lilly & Co. 1.12%163.901.1%$625.17m
AZNAstraZeneca Plc 1.37%53.971.2%$295.85m
RPRXRoyalty Pharma Plc -1.23%43.520.1%$177.86m
NVSNovartis AG 1.64%87.490.2%$141.38m
GSKGlaxoSmithKline Plc 1.57%40.700.2%$109.85m
RGENRepligen Corp. 1.90%124.847.1%$109.74m
NVONovo Nordisk A/S 0.52%65.490.1%$82.37m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 4.85%72.920.0%$63.74m
RETAReata Pharmaceuticals, Inc. -2.29%149.523.4%$63.69m
SNYSanofi 2.30%52.110.2%$63.07m

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.